Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
Clinical Pharmacology and Therapeutics
|
December 1, 1992
Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients
M L Chouinard, L L Martin, T Coffman, et al.
Molecular Cancer Therapeutics
|
August 13, 2009
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib
Ching Ching Leow, Jon Chesebrough, Karen T Coffman, et al.
Cancer Research
|
November 25, 2003
Differential EphA2 epitope display on normal versus malignant cells
Karen T Coffman, Min Hu, Kelly Carles-Kinch, et al.
Molecular Cancer Therapeutics
|
February 18, 2003
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer
Sulma I Mohammed, Bruce A Craig, Anthony J Mutsaers, et al.
Neoplasia (New York, N.Y.)
|
June 2, 2009
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors
Elizabeth M Bruckheimer, Christine A Fazenbaker, Sandra Gallagher, et al.
JCI Insight
|
February 8, 2022
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Eric Tu, Kelly McGlinchey, Jixin Wang, et al.
Journal of the National Cancer Institute
|
November 2, 2006
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer
Charles N Landen, Chunhua Lu, Liz Y Han, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
Clinical Pharmacology and Therapeutics
|
December 1, 1992
Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients
M L Chouinard, L L Martin, T Coffman, et al.
Molecular Cancer Therapeutics
|
August 13, 2009
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib
Ching Ching Leow, Jon Chesebrough, Karen T Coffman, et al.
Cancer Research
|
November 25, 2003
Differential EphA2 epitope display on normal versus malignant cells
Karen T Coffman, Min Hu, Kelly Carles-Kinch, et al.
Molecular Cancer Therapeutics
|
February 18, 2003
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer
Sulma I Mohammed, Bruce A Craig, Anthony J Mutsaers, et al.
Neoplasia (New York, N.Y.)
|
June 2, 2009
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors
Elizabeth M Bruckheimer, Christine A Fazenbaker, Sandra Gallagher, et al.
JCI Insight
|
February 8, 2022
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Eric Tu, Kelly McGlinchey, Jixin Wang, et al.
Journal of the National Cancer Institute
|
November 2, 2006
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer
Charles N Landen, Chunhua Lu, Liz Y Han, et al.
Page
of 3